Pre-surgical Evaluation of Denosumab in Patients With Operable Invasive Breast Cancer
Brief description of study
The goal of this Phase 0 (biomarker) study is to evaluate tumor-specific biomarkers of RANK/RANKL expression in early breast cancer. It will also provide insight into changes in the tumor microenvironment induced by the RANKL inhibitor, denosumab, which may decrease the ability of tumor to spread.
Clinical Study Identifier: s14-01311
ClinicalTrials.gov Identifier: NCTs14-01311
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
